On July 10, Minjung Seon, a researcher at Hana Financial Investment, stated, "The second-quarter earnings were weak due to being pre-reflected in the first quarter and deferred to the third quarter. Due to the expansion of flu vaccinations caused by the COVID-19 virus, record-high earnings are expected in the third quarter, and Green Cross, which is also developing a COVID-19 plasma treatment, can be considered a true beneficiary of COVID-19." She set the target price for Green Cross at 240,000 KRW.
Over the past five days, individual investors have net bought 123,946 shares of Green Cross, while foreigners and institutions have net sold 24,363 shares and 106,707 shares, respectively.

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

